荆志成，男，北京协和医院心内科主任。2018年当选北京协和医学院首批“长聘教授”。北京协和医学院内科学及遗传学两个专业方向博士研究生导师。中国农工民主党中央委员，中国农工民主党北京市委员会副主任委员，中国农工民主党第十六届中央医疗卫生工作委员会副主任，第十三届北京市政协委员，北京市人民政协理论与实践研究会第五届理事会成员。

1994年本科毕业于潍坊医学院获得医学学士学位，1998年获得北京协和医学院（原中国协和医科大学）内科学专业（心血管病方向）医学博士学位，同年留校于中国医学科学院阜外医院内科工作，历任内科住院医师，总住院医师，主治医师，副主任医师，硕士研究生导师。2004年11月-2006年10月留学法国巴黎十一大学留学，从事博士后研究。

2008年人才引进到同济大学工作，同年晋升为教授、内科学博士生导师，2009年晋升为主任医师。2013年人才引进回中国医学科学院阜外医院工作，历任内科副主任兼血栓中心主任，科研处处长等职务。2020年1月2日调入北京协和医院担任心内科主任。

截至2019年底，已荣获“国家杰出青年科学基金”、国家“万人计划”科技创新领军人才、百千万人才工程国家级人选暨有突出贡献的中青年专家、中国医师奖、国务院政府特殊津贴、中国侨界突出贡献一等奖、树兰医学青年奖、科技北京百名领军人才、上海市领军人才、上海市曙光学者、上海市银蛇奖等国家和省部级人才荣誉和奖项。

目前担任《中国介入心脏病学杂志》执行主编、《中华心血管病杂志》副总编辑、《中华医学杂志（英文版）》副总编辑、北京医学会血栓与止血分会主任委员、北京医学会心血管病学分会副主任委员、中华医学会心血管病分会结构性心脏病学组副组长、JACC Asia子刊 Section Editor。2019年当选世界肺高血压协会（WSPHA）首届科学委员会委员。2020年1月起，正式出任国际血栓与凝血学会（International Society of Thrombosis and Haemostasis, ISTH）官方旗舰杂志 Journal of Thrombosis and Haemostasis 副主编，主要负责静脉血栓形成与肺栓塞领域方向。

   截至2021年底，发表经同行评议SCI英文论文126篇，总计被引次数13100次，总影响因子1468.909分，h-index 41, i10 index 89。作为课题负责人承担“十三.五”国家重点研发项目、国家自然科学基金重点项目暨重大国际合作项目、北京市自然科学基金重点项目等国家和省部级纵向科研项目多项。作为Global steering committee member 和national leading PI or coordinator 等领导多项国际、国内多中心新药、注册登记等临床试验。2019年12月国际权威学术期刊-欧洲心脏杂志（Eur Heart J.2019,40:3881-3885）在世界优秀心血管中心专栏长篇报道了荆志成教授领导的团队二十年来在中国为心血管科学以及心血管疾病患者所付出的努力和取得的成就。2022年5月欧洲心脏杂志再次于学科领袖栏目（Leaders）专访赞誉荆志成教授为“中国肺血管病学先锋”。(European Heart Journal, Volume 43, Issue 17, Page1605–1608,   https://doi.org/10.1093/eurheartj/ehab634)

截止到2022年4月底，五十篇英文学术论文代表作：

1.Liu B, Wei YP, Fan X, Hu X, Chen Z, Liu X, Xu Y, Wang L, Wang T, Ruiz M, Dupuis J, Yuan P, Liu J, Huang S, Zhu L, Jing ZC, Hu Q. Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility. Hypertension 2022 Apr 28: 101161HYPERTENSIONAHA.121.18399. (IF=10.190, Co-Corresponding Author)

2.Zhou YP, Wei YP, Yang YJ, Xu XQ, Wu T, Liu C, Mei KY, Peng FH, Wang HP, Sun K, Li JY, Wang HF, Li MT, Wang DL, Miao Q, Jiang X, Jing ZC. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. J Am Coll Cardiol. 2022 Apr 19;79(15):1477-1488. (IF=24.094, Corresponding author)

3.Jiang X, Zhu YJ, Zhou YP, Peng FH, Wang L, Ma W, Cao YS, Pan X, Zhang GC, Zhang F, Fan FL, Wu BX, Huang W, Yang ZW, Hong C, Li MT, Wang YN, Xu XQ, Wang DL, Zhang SY, Jing ZC. Clinical features and survival in Taksyasu's arteritis-associated pulmonary hypertension: a nationwide study. Eur Heart J. 2021 Nov 7;42(42):4298-4305. (IF = 29.983, Corresponding author)

4.Lian TY, Lu D, Yan XX, Tan JS, Peng FH, Zhu YJ, Wei YP, Wu T, Sun K, Jiang X, Hua L, Jing ZC. Association between congenital thrombophilia and outcomes in pulmonary embolism patients. Blood Adv. 2020 Dec 8;4(23):5958-5965. (IF = 6.686, Corresponding author)

5.Yan Y, He YY, Jiang X, Wang Y, Chen JW, Zhao JH, Ye J, Lian TY, Zhang X, Zhang RJ, Lu D, Guo SS, Xu XQ, Sun K, Li SQ, Zhang LF, Zhang X, Zhang SY, Jing ZC. DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension. Science Advance. 2020 Dec 9;6(50):eaba2470. (IF = 14.136, Corresponding author)

6.Zhang SJ, Lian TY, Zhu XJ, Lu D, Xu XQ, Jiang X, Jing ZC. Derivation of an induced pluripotent stem cell line (PUMCHi003-A) from a patient with pulmonary arterial hypertension carrying heterozygous mutation in PTGIS gene. Stem Cell Res. 2020 Jul;46:101875. (IF = 2.02, Corresponding author)

7.He YY, Yan Y, Jiang X, Zhao JH, Wang Z, Wu T, Wang Y, Guo SS, Ye J, Lian TY, Xu XQ, Zhang JL, Sun K, Peng FH, Zhou YP, Mao YM, Zhang X, Chen JW, Zhang SY, Jing ZC, Spermine promotes pulmonary vascular remodeling and its synthase is a therapeutic target for pulmonary arterial hypertension. Eur Respir J. 2020 Nov 5;56(5):2000522. (IF = 16.671, Corresponding author)

8.Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, Cheng X, Jing ZC, Liu B, Chen J, Nie S, Zhu J, Li F, Ma C. CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic. Circulation. 2020;141(20):e810-816. (IF= 29.690, Guideline Co-Committee member)

9.Hasan B, Hansmann G, Budts W, Heath A, Hoodbhoy Z, Jing ZC, Koestenberger M, Meinel K, Mocumbi A, Radchenko G, Sallmon H, Sliwa K, Kumar R, on behalf of the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, CSC, PASCAR, PCS, and PCSI. Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions. J Am Coll Cardiol. 2020 May 19;75(19):2463-2477. (IF=24.094, Co-author)

10.Zhang J, He Y, Yan X, Shanshan Chen, Ming He, Yuyang Lei, Jiao Zhang, Brendan Gongol, Mingxia Gu, Yifei Miao, Liang Bai, Xiaopei Cui, Xiaojian Wang, Yixin Zhang, Fenling Fan, Zhao Li, Yuan Shen, Chih-Hung Chou, Hsien-Da Huang, Atul Malhotra, Marlene Rabinovitch, Jing ZC, John Y-J Shyy. MicroRNA-483 Amelioration of Experimental Pulmonary Hypertension. EMBO Mol Med. 2020 May 8;12(5):e11303. (IF=12.137, Co-corresponding Author)

11.Wang XJ, Xu XQ, Sun K, Liu KQ, Li SQ, Jiang X, Zhao QH, Wang L, Peng FH, Ye J, Wu Y, Jiang R, Zhang J, Huang W, Bei WB, Yan Y, Li JH, Liu QQ, Li S, Wang Y, Zhang SY, Zhang X, Jing ZC. Association of rare PTGIS variants with susceptibility and pulmonary vascular response in patients with idiopathic pulmonary arterial hypertension. JAMA Cardiol. 2020 Apr 1;5(6):677-684. (IF=14.676, Co-corresponding Author)

12.Jing ZC, Zhu HD, Yan XW, Chai WZ, Zhang SY, on behalf of the COVID-19 & AMI committee of Peking Union Medical College Hospital. Recommendations from Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. Eur Heart J. 2020 Mar 31;41(19):1791-1794. (IF=29.983, First Author)

13.Jiang X, Xu XQ, Jing ZC. The Key Laboratory of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences (KLPVM-CAMS). Eur Heart J. 2019 Dec 21;40(48):3881-3885. (IF=29.983, Corresponding Author)

14.Gu W, Ni Z, Tan YQ, Deng J, Zhang SJ, Lv ZC, Wang XJ, Chen T, Zhang Z, Hu Y, Jing ZC, Xu Q. Adventitial Cell Atlas of wt (Wild Type) and ApoE (Apolipoprotein E)-Deficient Mice Defined by Single-Cell RNA Sequencing. Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1055-1071. (IF=8.311, Co-corresponding Author)

15.Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019 Jan 24;53(1):1801889. (IF=16.671, Co Committee-member, Proceedings of the 6th World Symposium on Pulmonary Hypertension)

16.Wang XJ, Lian TY, Jiang X, Liu SF, Li SQ, Jiang R, Wu WH, Ye J, Cheng CY, Du Y, Xu XQ, Wu Y, Peng FH, Sun K, Mao YM, Yu H, Liang C, John YJ, Zhang SY, Zhang X, Jing ZC. Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension. Eur Respir J. 2019 Mar 14;53(3):1801609. (IF=16.671, Corresponding Author)

17.Wu WH, Yuan P, Zhang SJ, Jiang X, Wu C, Li Y, Liu SF, Liu QQ, Li JH, Pudasaini B, Hu QH, Dupuis J, Jing ZC. Impact of Pituitary–Gonadal Axis Hormones on Pulmonary Arterial Hypertension in Men. Hypertension. 2018 Jul;72(1):151-158. (IF=10.190, Corresponding Author)

18.Ghofrani H-A, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jais X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH, on behalf of the MERIT study investigators. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017 Oct;5(10):785-794.     (IF=30.700, Steering Committee Member of this Global study)

19.Zhang HD, Lv ZC, Wang LT, Rothman A, Lian TY, He YY, Wu Y, Lawrie A, Beghetti M, Jing ZC. Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2017 Dec 1;196(11):1478-1481. (IF=21.405, Corresponding Author)

20.Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Insights into Pulmonary Vascular Disease (PVD) Through a Precision Medicine Approach. A Joint NHLBI-CMREF Workshop Report. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. (IF=21.405, invited Committee Member)

21.Liu D, Yan Y, Chen JW, Yuan P, Wang XJ, Jiang R, Wang L, Zhao QH, Wu WH, Simonneau G, Qu JM, Jing ZC. Hypermethylation of BMPR2 Promoter Occurs in the Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. Am J Respir Crit Care Med. 2017 Oct 1;196(7):925-928. (IF=21.405, Corresponding Author)

22.Zhang R, Wang XJ, Zhang HD, Sun XQ, Zhao QH, Wang L, He J, Jiang X, Liu JM, Jing ZC. Profiling nitric-oxide metabolites in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2016 Nov;48(5):1386-1395 (IF=16.671, Corresponding Author)

23.Ghofrani HA, Grimminger F, Grunig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomized long-term extension trial. Lancet Respir Med. 2016 May;4(5):361-371. (IF=30.700, Co-author)

24.Liu D, Wu BX, Sun N, Yan Y, Yuan P, Qu JM, Jing ZC. Elevated levels of circulating BMP7 predict mortality in pulmonary arterial hypertension. Chest. 2016 Aug;150(2):367-73. (IF=9.410, Corresponding Author)

25.Hoeper M, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, Jing ZC, Gibbs JS R. A global view of pulmonary hypertension. Lancet Respir Med. 2016 Apr;4(4):306-322. (IF=30.700, Co-author in this invited review)

26.Evans JD, Girerd B, Montani D, Wang XJ, Austin ED, Elliott G, Asano K, Grunig E, Yan Y, Jing ZC, Manes A, Palazzini M, Wheeler LA, Nakayama I, Satoh T, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig EB, Chung WK, Soubrier F, Simonneau G, Sitbon O, Graf S, Kaptoge S, Di Angelantonio E, Humbert M, Morrell NW.  BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016 Feb;4(2):129-137. (IF=30.700, Co-author)

27.Wen L, Sun ML, An P, Jiang X, Sun K, Zheng L, Liu QQ, Wang L, Zhao QH, He J, Jing ZC. Frequency of Supraventricular Arrhythmias in Patients With Idiopathic Pulmonary Arterial Hypertension. Am J Cardiol. 2014 Nov 1;114(9):1420-1425. (IF=2.778, Corresponding Author)

28.Hao YJ, Jiang X, Zhou W, Wang Y, Gao L, Wang Y, Li GT, Hong T, Huo Y, Jing ZC, Zhang ZL. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J. 2014 Oct;44(4):963-972 (IF=16,671, Co-author)

29.Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J,Seeger W, Keogh A. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2014 Oct;42 Suppl 1:78-94. (IF=24.094, Co-Task Force Committee member, this article is WHO Guideline)

30.Pulido T, Adzerikho I, Channick R, Delcroix M, Galie N, Chofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer C, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng XF, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med. 2013 Aug 29;369(9):809-818. (IF=94.444, Steering Committee Member of this Global study )

31.Fan YF, Zhang R, Jiang X, Wen L, Wu DC, Liu D, Yuan P, Wang YL, Jing ZC. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. Cardiovasc Res. 2013 Aug 1;99(3):395-403. (IF=10.787, Corresponding Author)

32.Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, and Rubin LJ, for the PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25;369(4):330-340.(IF=94.444, Co-author, Steering Committee Member of this Global study)

33.Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Arneson C, Laliberte K, and Rubin LJ. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized controlled trial. Circulation. 2013 Feb 5;127(5):624-633. (IF=26.690, 1st and Corresponding Author)

34.Wu WH, Yang L, Peng FH, Yao J, Zou LL, Liu D, Jiang X, Li J, Gao L, Qu JM, Kawut SM, Jing ZC. Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013 Feb 1;187(3):303-310 (IF=21.405, Corresponding Author)

35.Yuan P, Wu WH, Gao L, Zheng ZQ, Liu D, Mei HY, Zhang ZL, Jing ZC. Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, PGI2 and ET-1 pathways. Eur Respir J. 2013 May;41(5):1116-1125. (IF=16.671, Corresponding Author)

36.Zhao QH, Peng FH, Wei H, He J, Chen FD, Di RM, Jiang X, Jiang R, Chen YJ, GA Heresi, Jing ZC. Serum High-Density Lipoprotein Cholesterol Levels as a Prognostic Indicator in Patients with Idiopathic Pulmonary Arterial Hypertension. Am J Cardiol. 2012 Aug 1;110(3):433-439 (IF=2.778, Corresponding Author)

37.Berger RMF, Beghetti M, Humpl T, Raskob GE, lvy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ. Clinical features of paediatric pulmonary hypertension: a regisrty study. Lancet. 2012 Feb11;379(9815):537-546. (IF=79.321, Co-author)

38.Zhang ZN, Jiang X, Zhang R, Li XL, Wu BX, Zhao QH, Wang Y, Dai LZ, Pan L, Gomberg-Maitland M, Jing ZC. Oral Sildenafil thearpy for Eisenmenger Syndrome: A prospective, open-label, multicenter study. Heart. 2011 Nov;97(22):1876-1881. (IF=5.994, Corresponding Author)

39.Sun PY, Jiang X, Gomberg-Maitland M, Zhao QH, He J, Yuan P, Zhang R, Jing ZC. Prolonged QRS Duration: A New Predictor of Adverse Outcome in Idiopathic Pulmonary Arterial Hypertension. Chest. 2012 Feb;14(12):374-380. (IF=9.410, Corresponding Author)

40.Liu D, Liu QQ, Melanie E, Wu WH, Yuan P, Zhang R, Soubrier F, Jing ZC. Molecular Genetics and Clinical Features of Chinese IPAH and HPAH Patients. Eur Respir J. 2012 Mar;39 (3):597-603 (IF=16.671, Corresponding Author)

41.Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, Pan L, Zhang ZL, Liu XQ, Zhang YS, Jiang X, Galiè Nfor the Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study. Vadenafil in Pulmonary Arterial Hypertension: A Randomized, Double-blind, Placebo-controlled Study. Am J Respir Crit Care Med. 2011 Jun 15;183(12):1723-1729. (IF=21.405, 1st and Corresponding Author)

42.Zhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, Yuan P, Jiang X, He J, Humbert M, Jing ZC. Survival of Chinese Patients with Pulmonary Arterial Hypertension in the Modern Management Era. Chest. 2011 Aug;140(2):301-309.（IF=9.410, Corresponding Author）

43.Jing ZC, Strange G, Zhu XY, Zhou DX, Shen JY, Gu H, Yang ZK, Pan X, Xiang MX, Yao H, Zhao DB, Dalton BS, Zhang ZL, Wang Y, Cheng XS, Yang YJ. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb;29(2):150-156. (IF=10.247, 1st and Corresponding Author)

44.Jing ZC, Jiang X, Wu BX, Xu XQ, Wu Y, Ma CR, Wang Y, Yang YJ, Pu JL, Gao W. Vardenafil Therapy for Patients with Pulmonary Arterial Hypertension: a multicentre open-label study. Heart. 2009 Sep;95:1531-1536. (IF=5.994, 1st and Corresponding Author)

45.Xu XQ, Jing ZC. High-altitude pulmonary hypertension. Eur Respir Rev. 2009 Mar 1;18(111):13-17. (IF=8,839, Corresponding Author)

46.Jing ZC, Jing X, Han ZY, Xu XQ, Wang Y, Wu Y, Lv H, Ma CR, Yang YJ, Pu JL. Iloprost for Pulmonary Vasodilator Testing in Idiopathic Pulmonary Arterial Hypertension. Eur Respir J. 2009 Jun;33:1354-1360. (IF=16.671, 1st and Corresponding Author)

47.Simonneau G, Robbins IM, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1):S43-S54. (IF=24.094, Co-Committee Member, this article is WHO guideline)

48.Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, Wang ZW, Cheng XS, Xu B, Hu SS,Hui RT, Yang YJ. Registry and survival study of Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007 Aug;132:373-379. (IF=9.410, 1st and Corresponding Author)

49.Hoeper MM, Lee SH, Vosswinckel R, Galie N, Jais X, Manes A, Barst RJ, Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, Oudiz Ron, Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin LJ. Complications of Right Heart Catheterization Procedures in patients with Pulmonary Hypertension. J Am Coll Cardiol. 2006 Dec 19;48(12):2546-2552. (IF=24.094, Co-author)

50.Jing ZC, Lu LH, Han ZY, Cheng XS, Zou YB, Yang YJ, Hui RT. Bone Morphogenetic Protein Receptor-2 Mutation Arg491Trp causes malignant phenotype of Familial Primary Hypertension. Biochem Biophys Res Commun. 2004 Mar 19;(315):1033-1038. (IF=3.575, 1st Author)

截止至2021年10月中文核心期刊代表作：

1.陈茂, 荆志成, 张浩, 陈飞, 经导管三尖瓣置换治疗的现状与挑战. 中华心血管病杂志, 2021,49(5):420-424.

2.徐希奇, 田庄, 方全, 荆志成, 张抒扬, 北京协和医院经皮心内膜心肌活检临床操作规范. 中华心血管病杂志, 2021,49(1):12-16.

3.荆志成, 张抒扬, 科学应对新型冠状病毒肺炎与心血管急症的双面夹击. 中华心血管病杂志, 2020,48(3):175-176.

4.路丹, 周玉杰, 荆志成, 警惕布鲁病性心内膜炎. 中华心血管病杂志, 2020,48(11):901-905.

5.荆志成. 我在协和做住院医的那一年.中华心血管病杂志, 2019,47(11):851-853. (总编随笔)

6.中华医学会心血管病学分会肺血管病学组 中华心血管病杂志编辑委员会. 中国肺高血压诊断和治疗指南2018. 中华心血管病杂志, 2018,46(12):933-964.

7.荆志成. 十年磨一剑. 中华心血管病杂志, 2018,46(12):918-920. (述评)

8.荆志成. 我的博士学位论文. 中华心血管病杂志, 2018,46(12):915-917. (总编随笔)

9.荆志成. 我们还需要向西方学习多久：艾森曼格医师留给我们的机遇和挑战. 中华心血管病杂志, 2017,45(12):1005-1007. (总编随笔)

10.王晓建 张宏达 荆志成. 星星之火可以燎原：肺动脉高压从传统诊疗走向精准医学的20年. 中华心血管病杂志, 2017,45(6):476-479.

11.中华医学会心血管病学分会肺血管病学组 中华心血管病杂志编辑委员会. 急性肺栓塞诊断与治疗中国专家共识 2015. 中华心血管病杂志, 2016,44(3):197-211.

12.连天宇，严欣欣，荆志成. 急性肺栓塞的临床实践-中国医学科学院阜外医院血栓中心临床经验. 中华心血管病杂志, 2016,44(3):186-190.

13.荆志成，王鸿懿，张宇清，胡大一. 代表北京医学会心血管病学分会青年委员会，2013 年国 际高血压指南热点争鸣：降压治疗目标值是多少？中华心血管病杂志, 2014,42(7):611-615.

14.文莉，蒋鑫，安培，何晶，郑璐，刘倩倩，彭富华，徐希奇，荆志成. 安立生坦单药治疗肺动脉高压患者的长期疗效观察.中华心血管病杂志, 2014,42(6):469-473.

15.荆志成，徐希奇. 攻克肺动脉高压的长征之路：虽艰难但前途光明. 中华内科杂志, 2013,52(8):628-630.

16.何晶，文莉，姜蓉，赵勤华，王岚，蒋鑫，颜平，白蕾，荆志成. 安立生坦治疗肺动脉高压患者的初步观察. 中华心血管病杂志, 2013,41(6):347.

17.荆志成. 加强专科医师培养提高我国肺血管疾病防治能力. 中华心血管病杂志, 2011,39(10):881-882.（述评）

18.蒋鑫, 陈发东, 何晶, 姜蓉, 邸若岷, 赵勤华, 荆志成. 肺静脉闭塞病的临床特点和预后分析. 中华心血管病杂志, 2011,39(10):896-900.

19.袁平, 吴文汇, 刘岽, 张锐, 荆志成. 改良右心导管测量大鼠肺血管阻力的实验研究. 中华心血管病杂志, 2011,39(10):901-904.

20.代立志, 蒋鑫, 王勇, 余再新, 吴炳祥, 荆志成. 波生坦治疗特发性肺动脉高压患者的疗效及安全性. 中华心血管病杂志, 2011,39(2):124-127.

21.赵勤华, 徐希奇, 荆志成等. 心电图对肺动脉高压的诊断价值探讨.中华心血管病杂志, 2010,38(4):346-349.

22.荆志成, 胡大一. 急性肺血栓栓塞症诊断治疗中国专家共识. 中华内科杂志, 2010,49(1):74-81.

23.荆志成, 徐希奇. 蒋鑫, 经前臂静脉径路行右心导管检查和肺动脉造影的可行性研究. 中华心血管病杂志, 2009,37(2):142-144.

24.荆志成, 徐希奇. 波生坦治疗肺动脉高压患者的初步结果. 中华医学杂志, 2008,88(30):2136-2139.

25.荆志成. 6分钟步行距离的临床应用.中华心血管病杂志, 2006, 34(4) :183-186.

26.高润霖, 荆志成. 心血管内科专科医师培养基地细则. 中国实用内科杂志, 2006,26(7):557.

27.荆志成, 徐希奇. 肺动脉高压现代分类和诊断策略. 中华心血管病杂志, 2004,32(12):1160-1162.

28.荆志成, 邓可武. 急性肺动脉栓塞症的溶栓治疗. 中华医学杂志, 2004, 84(22):1932-1933.

29.荆志成等. 急性高侧壁、正后壁心肌梗塞并发亚急性心脏破裂、心包填塞1例. 中华心血管病杂志, 2003,31(6):463.

30.荆志成等. 中国汉族人群家族性原发性肺动脉高压2例及文献复习. 中华结核与呼吸病杂志, 2002,25(11):684-685.

31.荆志成, 程显声, 韩志岩等. 盐酸芬氟拉明致原发性肺动脉高压2例及文献复习. 中华医学杂志, 2002,82(19):1362-1363.

32.荆志成, 王辰, 程显声. 原发性肺动脉高压临床诊断方法. 中华结核与呼吸病杂志, 2002,25(8):500-502.

33.荆志成, 韩志岩. 静脉血栓形成研究动向. 中华结核与呼吸疾病杂志, 2000, 23(9):522-523.（专题笔谈）

34.荆志成, 程显声, 杨英珍等. 病毒性心肌炎急性期预防性干预心脏间质纤维化的实验研究. 中华医学杂志, 1998,78(9):699-701.

35.荆志成, 程显声. 心脏胶原网络及其病理学意义. 中国循环杂志, 1998, 13(3):187-188.